絞り込み

16641

広告

疑問氷解:人間に育てられた犬や猫は、動物の言葉はわからないのですか? - 毎日新聞

Q 人間(にんげん)に育(そだ)てられた犬(いぬ)や猫(ねこ)は、動物(どうぶつ)の言葉(ことば)はわからないのですか?(福岡県北九州市(ふくおかけんきたきゅう...

  1. [医学] 手や腕の動作に携わる脳の運動皮...
  2. SRC/ABLチロシンキナーゼ阻害薬ボス...
  3. 最初の再発を起こした高/中間リスク若年B...
  4. 再発・難治性多発性骨髄腫へのKdDはKd...

ニュース一覧

Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.

著者 Sherbenou DW , Mark TM , Forsberg P
Clin Lymphoma Myeloma Leuk.2017 Jun 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (414view , 0users)

Full Text Sources

Medical

In 2015, 2 monoclonal antibodies were approved for the treatment of relapsed or refractory multiple myeloma (RRMM), elotuzumab and daratumumab. Elotuzumab is a monoclonal IgG-κ antibody directed against SLAMF7 (signaling lymphocytic activation molecule F7), a cell surface receptor involved in natural killer cell activation. Daratumumab is a monoclonal IgG-κ antibody that binds to CD38, a transmembrane protein found on the surface of myeloma cells and responsible for cellular adhesion and ectoenzymatic activity. Both elotuzumab and daratumumab act through recruitment of the immune system to enhance cellular cytotoxicity directed against myeloma cells. Elotuzumab requires lenalidomide and dexamethasone combined to enhance progression-free survival in patients with RRMM, and daratumumab has both single-agent and combination activity with either lenalidomide or the proteasome inhibitor bortezomib in RRMM. The adverse effect profile of both agents mainly consists of allergic-type infusion reactions. Other considerations for monoclonal antibody use in the treatment of MM include the potential for interference in serum protein electrophoresis testing and cross-reactivity of daratumumab with CD38 present on red blood cells. In the present report, we discussed the clinical development of daratumumab and elotuzumab and newer immunologic approaches to the treatment of MM.
PMID: 28734795 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード